Conference
A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29
Authors
Laurie SA; Solomon BJ; Seymour L; Ellis PM; Goss GD; Shepherd FA; Boyer MJ; Arnold AM; Clingan P; Laberge F
Volume
30
Publisher
AMER SOC CLINICAL ONCOLOGY
Publication Date
May 20, 2012
Name of conference
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
Chicago, IL
Conference start date
June 1, 2012
Conference end date
June 6, 2012
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
15
ISSN
0732-183X